Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

HJ Science (华健未来) Pre-IPO: Clinical Evidence Needed for Pipeline Breadth

HJ Science (华健未来) Pre-IPO: Thoughts on Valuation

HJ Science (华健未来) IPO: Analysis of Deal Terms

Equity Capital Markets

<ul>
<li>HJ Science, a clinical-stage biotech company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$81.80 per share.</li>
<li>The company intends to raise HK$1,112M, primarily to fund ongoing and planned R&amp;D activities for pipeline products, mainly for the late-stage trials and registration of core product candidate HJ787.</li>
<li>The subscription period will close on June 17, 2026, with the shares expected to make trading debut on June 23, 2026. Citic Securities is the sole sponsor to the issue.</li>
</ul>


HJ Science, a clinical-stage biotech company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$81.80 per share.
The company intends to raise HK$1,112M, primarily to fund ongoing and planned R&amp;D activities for pipeline products, mainly for the late-stage trials and registration of core product candidate HJ787.
The subscription period will close on June 17, 2026, with the shares expected to make trading debut on June 23, 2026. Citic Securities is the sole sponsor to the issue.


HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect